Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The lesson being "read first".
What about Bavi for crops?
So you're telling me there's a chance...
All the best,
John
From your conversations with KOL's do you believe Bavituximab is therapeutic as is?
All the best,
John
North40000,
Biopharm,
Biopharm and Phophoantigens,
KT,
What exactly is "PS Targeting"?
It's loosely thrown around, and without any explanation of what and how. Just vague, directionless chatter, much like the drug itself, IMO.
All the best,
John
This is called, "endogenous protein cross reactivity".
In other words a lot of biologic competition for a clumsy therapeutic, IMO.
They could theoretically eliminate some competition by introducing specific statin combination that would reduce b2gp1 antigen presentation (from domain V2 epitope) to LDL receptor. Just saying..
Also, if ever a molecule needed exact PK data, this would be it.
All the best,
John
BCLI get's 16M Non-dilutive funding for ALS NurOwn Phase III study.
http://ir.brainstorm-cell.com/phoenix.zhtml?c=142287&p=irol-newsArticle&ID=2287895
All the best,
John
Focus on Avid?
Did Ronin's shares get split?
All the best,
John
Peregrine has hit the reset button for the 3rd time. A fresh path of dilution is set. They would be wise to know Bavituximab's curve of diminishing returns, as related cross reactivity and optimal dosage.
Start there.
All the best,
John
This is correct..
Now if it would have been designated as "Breakthrough" then it would be at $5.00 right now.
This needs to be validated through trial (Phase II)
All the best,
John